Sanofi to acquire Vicebio in $1.15bn deal to expand RSV and hMPV vaccine pipeline

Sanofi (EURONEXT: SAN, NASDAQ: SNY) is deepening its presence in respiratory vaccines and rare immunology diseases through two strategic acquisitions. On July 22, 2025, the French biopharmaceutical giant announced a definitive agreement to acquire London-based Vicebio Ltd, a biotechnology company specializing in next-generation respiratory virus vaccines. Just days earlier, Sanofi completed its acquisition of Blueprint Medicines Corporation, adding to its rare immunology portfolio, including the only approved systemic mastocytosis (SM) treatment, Ayvakit/Ayvakyt (avapritinib). Together, these moves strengthen Sanofi’s ambition to dominate in both respiratory and immunological therapeutics.

How does Sanofi’s Vicebio acquisition expand its respiratory vaccines strategy and leverage molecular clamp technology for combination vaccines?

Sanofi’s planned $1.15 billion upfront acquisition of Vicebio, with additional milestone payments of up to $450 million, marks a significant step in its respiratory vaccine expansion. Vicebio’s leading candidate, VXB-241, is a bivalent vaccine for respiratory syncytial virus (RSV) and human metapneumovirus (hMPV), now in exploratory phase 1 studies in older adults. Its preclinical trivalent candidate, VXB-251, also targets parainfluenza virus Type 3 (PIV3). These three viruses are major contributors to seasonal respiratory illness surges, which frequently lead to hospitalization and increased mortality among older adults.

Institutional investors view the acquisition as an efficient way for Sanofi to diversify beyond mRNA vaccines, with Vicebio’s “Molecular Clamp” technology seen as a differentiator. This platform stabilizes viral proteins in their native form, enabling robust immune responses and supporting fully liquid vaccine formulations. Such vaccines, which can be stored at standard refrigeration temperatures (2–8°C), are expected to simplify global distribution logistics and increase healthcare provider adoption. Analysts also suggest that this acquisition could position Sanofi as a preferred supplier in markets prioritizing non-mRNA alternatives for multi-pathogen protection.

Sanofi’s Global Head of Research and Development Vaccines indirectly emphasized that the company aims to use Vicebio’s platform to develop next-generation combination vaccines offering single-shot protection against multiple respiratory viruses for older adults, aligning with broader public health goals.

What does the Blueprint Medicines acquisition reveal about Sanofi’s rare immunology strategy and its potential financial impact?

The completed Blueprint Medicines acquisition further underscores Sanofi’s long-term rare disease strategy. Valued at $129 per share in cash plus up to $6 per share in contingent milestone payments, the deal makes Blueprint a wholly owned subsidiary. Financing was secured through a mix of cash reserves and commercial paper issuances. The acquisition is expected to be immediately accretive to Sanofi’s gross margin and to business operating income and earnings per share (EPS) starting 2026.

Blueprint brings to Sanofi its commercialized rare immunology drug Ayvakit/Ayvakyt (avapritinib), the first and only approved treatment for advanced and indolent systemic mastocytosis (ASM & ISM). The drug is approved across 16 countries, including China, where it is marketed by CStone Pharmaceuticals under a royalty agreement. Ayvakit/Ayvakyt is indicated for adults with SM variants such as aggressive SM, SM with an associated hematological neoplasm (SM-AHN), and mast cell leukemia (MCL), as well as gastrointestinal stromal tumors (GIST) with specific PDGFRA mutations.

Additionally, Blueprint’s pipeline includes elenestinib, a next-generation KIT D816V inhibitor undergoing phase 2/3 trials under the HARBOR study (NCT04910685), and BLU-808, a wild-type KIT inhibitor targeting mast cell activation in inflammatory diseases. The acquisition also strengthens Sanofi’s commercial footprint among allergists, dermatologists, and immunologists, potentially accelerating future immunology launches.

Market observers interpret the acquisition as part of Sanofi’s strategic shift to secure durable revenue streams from specialty rare diseases, where competition remains limited and pricing power is strong. Analysts have also noted that Blueprint’s portfolio could complement Sanofi’s existing immunology pipeline, particularly in allergy-driven and KIT-related disorders, giving the French drugmaker a broader therapeutic base.

How are institutional investors assessing Sanofi’s dual acquisitions in terms of strategic alignment and growth potential?

Institutional sentiment around the dual acquisitions remains cautiously optimistic. Analysts broadly agree that the Vicebio deal complements Sanofi’s existing flu and RSV portfolio while diversifying its vaccine technology base beyond mRNA approaches. Its focus on liquid formulations stored at standard temperatures is seen as a logistical advantage for emerging markets and healthcare systems with limited cold-chain infrastructure.

On the Blueprint front, institutional investors consider the acquisition a low-risk, high-reward addition, given Ayvakit/Ayvakyt’s already approved status and the relatively small competitive landscape in systemic mastocytosis. The immediate gross margin accretion and projected EPS growth after 2026 are expected to improve Sanofi’s long-term profitability. However, some caution remains around clinical trial risks for Blueprint’s investigational candidates, especially elenestinib and BLU-808.

Sanofi’s management has maintained that neither acquisition will significantly alter its 2025 financial guidance, which reassures investors wary of large-scale integration risks. Yet, the strategic value of expanding into high-need therapeutic categories—respiratory combination vaccines and rare immunology—appears to outweigh near-term risks in the eyes of most institutional stakeholders.

What are the broader implications of these acquisitions for Sanofi’s competitive positioning in vaccines and immunology markets?

Sanofi’s back-to-back acquisitions signal an accelerated push to diversify its revenue base and maintain relevance in competitive markets dominated by rivals such as Pfizer in RSV and Regeneron in immunology. With Vicebio, Sanofi gains early-stage combination vaccine capabilities that could appeal to healthcare systems seeking single-dose protection solutions for older adults. The Molecular Clamp technology also provides a scalable manufacturing advantage at a time when global demand for respiratory vaccines continues to grow.

Blueprint positions Sanofi as a rare immunology leader, strengthening its relationships with specialist prescribers and paving the way for future combination therapies targeting mast cell activation and inflammatory pathways. The dual acquisitions align with Sanofi’s stated goal of using AI-powered R&D to chase “miracles of science,” a strategy designed to improve both patient outcomes and long-term shareholder value.

Going forward, analysts expect Sanofi to intensify its focus on selective acquisitions in specialty therapeutics and next-generation vaccine platforms, positioning itself as a long-term consolidator of high-value biotech innovation. Institutional investors believe the Vicebio and Blueprint transactions illustrate a deliberate shift toward bolt-on acquisitions that balance early-stage platform technologies with commercialized rare disease assets. The Vicebio deal, in particular, highlights Sanofi’s willingness to invest in differentiated vaccine technologies such as molecular clamp platforms that could accelerate the development of single-shot combination vaccines for RSV, hMPV, and other co-circulating respiratory viruses.

In parallel, the Blueprint Medicines acquisition underscores a strategy of securing approved rare disease drugs with strong pricing power and limited competition, creating durable revenue streams while expanding relationships with specialist prescribers. Market observers expect future deals to target companies with proprietary immunology or virology platforms, especially those with late-stage or marketed products in areas like systemic mastocytosis, autoimmune disorders, and multi-pathogen respiratory immunization.

If executed consistently, such acquisitions could enable Sanofi to close competitive gaps with Pfizer and Moderna in respiratory vaccines and rival Regeneron and AbbVie in immunology, while diversifying beyond mRNA-based modalities. This acquisition-driven model also aligns with Sanofi’s broader goal of leveraging AI-powered R&D to shorten development timelines and reduce manufacturing complexity, a factor increasingly valued by payers and regulators. Institutional sentiment suggests that investors may reward Sanofi with higher valuation multiples if it continues to deliver bolt-on deals that are immediately accretive to gross margins and EPS, as projected for Blueprint Medicines after 2026.